复方阿嗪米特联合胃肠动力药治疗功能性消化不良Meta分析  

Meta- Analysis: Combination Therapy of Compound Azintamide and Gastrointestinal Prokinetic Drug in Patients with Functional Dyspepsia

作　　者：吴晓尉[1] 季洪赞[1] 许莲娥[1] 汪芳裕[1] 傅水明 

机构地区：[1]中国人民解放军南京军区南京总医院消化内科,江苏南京210002

出　　处：《中国药业》2015年第15期25-28,共4页China Pharmaceuticals

摘　　要：目的系统评价复方阿嗪米特联合胃肠动力药治疗功能性消化不良(FD)的疗效。方法通过中国知网(CNKI),中国生物医学文献数据库(CBM),PubMed,EMBASE,Cochrane Library等数据库,检索有关复方阿嗪米特联合胃肠动力药对比单用胃肠动力药治疗FD的随机对照试验,应用RevMan 5.3软件行Meta分析。结果共23个研究,包括2 412例FD患者纳入分析。复方阿嗪米特联合胃肠动力药治疗FD的总有效率显著高于单用胃肠动力药(RR=1.38,95%CI=1.29-1.47)。各项研究均未报道严重不良反应。结论复方阿嗪米特联合胃肠动力药可明显提高FD的疗效,且安全性较高。Objective To systematically evaluate the effect of combination therapy of compound azintamide and gastrointestinal prokinetic drug in patients with FD. Methods China National Knowledge Infrastructure （CNKI）, China Biology Medicine disc （CBM）, PubMed, EMBASE and Cochrane Librarywas were retrieved to collect randomized controlled trials that compared the effect of compound azin-tamide plus gastrointestinal prokinetic drug with simplex gastrointestinal prokinetic drug. Meta - analysis was performed with RevMan 5. 3 software. Results Twenty - three studies involving 2 412 FD patients were enrolled. The total effective rate in treatment group was sig-nificantly higher than that in control group （ RR = 1. 38, 95% CI = 1. 29 - 1. 47） . All the studies had not report serious adverse events. Conclusion Combination therapy of compound azintamide and gastrointestinal prokinetic drug can improve the efficacy of FD with high safety. The findings should be interpreted cautiously due to low quality of included studies and potential biases.

关 键 词：复方阿嗪米特 胃肠动力药 功能性消化不良 系统评价 

分 类 号：R969.3[医药卫生—药理学] R975.1[医药卫生—药学]